D’Angelo SP, Richards AL, Conley AP, Woo HJ, Dickson MA, Gounder M, Kelly C, Keohan ML, Movva S, Thornton K, Rosenbaum E, Chi P, Nacev B, Chan JE, Slotkin EK, Kiesler H, Adamson T, Ling L, Rao P, Patel S, Livingston JA, Singer S, Agaram NP, Antonescu CR, Koff A, Erinjeri JP, Hwang S, Qin LX, Donoghue MTA, Tap WD. Pilot study of bempegaldesleukin in combination with nivolumab in patients with metastatic sarcoma. Nat Commun. 2022; PMID: 35710741

Nacev BA*, Sanchez-Vega F*, Smith SA, Antonescu CR, Rosenbaum E, Shi H, Tang C, Socci ND, Rana S, Gularte-Mérida R, Zehir A, Gounder MM, Bowler TG, Luthra A, Jadeja B, Okada A, Strong JA, Stoller J, Chan JE, Chi P, D’Angelo SP, Dickson MA, Kelly CM, Keohan ML, Movva S, Thornton K, Meyers PA, Wexler LH, Slotkin EK, Glade Bender JL, Shukla NN, Hensley ML, Healey JH, La Quaglia MP, Alektiar KM, Crago AM, Yoon SS, Untch BR, Chiang S, Agaram NP, Hameed MR, Berger MF, Solit DB, Schultz N, Ladanyi M, Singer S, Tap WD. Clinical sequencing of soft tissue and bone sarcomas delineates diverse genomic landscapes and potential therapeutic targets. Nat Commun. 2022; PMID: 35705560

Chi P, Qin LX, Camacho N, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Francis JH, Martindale M, Phelan HT, Biniakewitz MD, Lee CJ, Singer S, Hwang S, Berger MF, Chen Y, Antonescu CR, Tap WD. Phase Ib Trial of the Combination of Imatinib and Binimetinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST). Clin Cancer Res. 2022; PMID: 35110417.

Chi P, Qin LX, Nguyen B, Kelly CM, D’Angelo SP, Dickson MA, Gounder MM, Keohan ML, Movva S, Nacev BA, Rosenbaum E, Thornton KA, Crago AM, Yoon S, Ulaner G, Yeh R, Martindale M, Phelan HT, Biniakewitz MD, Warda S, Lee CJ, Berger MF, Schultz ND, Singer S, Hwang S, Chen Y, Antonescu CR, Tap WD. Phase II Trial of Imatinib Plus Binimetinib in Patients With Treatment-Naive Advanced Gastrointestinal Stromal Tumor. J Clin Oncol. 2022; PMID: 35041493.

Klemen ND, Hwang S, Bradic M, Rosenbaum E, Dickson MA, Gounder MM, Kelly CM, Keohan ML, Movva S, Thornton KA, Chi P, Nacev BA, Chan JE, Bartlett EK, Richards AL, Singer S, Donoghue MTA, Tap WD, D’Angelo SP. Long-term Follow-up and Patterns of Response, Progression, and Hyperprogression in Patients after PD-1 Blockade in Advanced Sarcoma. Clin Cancer Res. 2021; PMID: 34965948.

Angeles CV, Velez-Rosborough A, Rios J, Laxa B, Shum D, Ruiz PD, Shen Y, Ostrovnaya I, Gularte Mérida R, Nacev BA, Dickson MA, Djaballah H, Okada T, Singer S. A High-Content Screen for C/EBPα Expression Identifies Novel Therapeutic Agents in Dedifferentiated Liposarcoma. Clin Cancer Res. 2021; PMID: 34667024.

Bagert, J.D., Mitchener, M.M, Patriotis, A.L., Dul, B.E., Wojcik, F., Nacev, B.A., Feng, L., Allis, C.D. and Muir, T.W. Oncohistone mutations enhance chromatin remodeling and alter cell fates. Nat Chem Biol 2021. PMID: 33649601

Rosenbaum E, Jonsson P, Seier K, Qin LX, Chi P, Dickson M, Gounder M, Kelly C, Keohan ML, Nacev B, Donoghue MTA, Chiang S, Singer S, Ladanyi M, Antonescu CR, Hensley ML, Movva S, D’Angelo SP, Tap WD. Clinical Outcome of Leiomyosarcomas With Somatic Alteration in Homologous Recombination Pathway Genes. JCO Precis Oncol. 2020; PMID: 33283135.

Rosenbaum E, Seier K, Bandlamudi C, Dickson M, Gounder M, Keohan ML, Chi P, Kelly C, Movva S, Nacev B, Simeone N, Donoghue M, Slotkin EK, Qin LX, Antonescu CR, Tap WD, D’Angelo SP. HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome. Clin Cancer Res. 2020 PMID: 32816945.

Nacev BA, Jones KB, Intlekofer AM, Yu JSE, Allis CD, Tap WD, Ladanyi M, Nielsen TO. The epigenomics of sarcoma. Nat Rev Cancer. 2020 PMID: 32782366.

Nacev BA, Feng L, Bagert JD, Lemiesz AE, Gao J, Soshnev AA, Kundra R, Schultz N, Muir TW, Allis CD. The expanding landscape of ‘oncohistone’ mutations in human cancers. Nature. 2019 Mar 20. 2019 Mar;567(7749):473-478.

Commentary: Jay F. Sarthy, Steven Henikoff; Bringing Oncohistones into the Fold. Cancer Discov 1 October 2019; 9 (10): 1346–1348. 

Head SA, Shi WQ, Yang EJ, Nacev BA, Hong SY, Pasunooti KK, Li RJ, Shim JS, Liu JO. Simultaneous Targeting of NPC1 and VDAC1 by Itraconazole Leads to Synergistic Inhibition of mTOR Signaling and Angiogenesis. ACS Chemical Biology. 2016 Nov.

Kshitiz, Afzal J, Suhail Y, Ahn EH, Goyal R, Hubbi ME, Hussaini Q, Ellison DD, Goyal J, Nacev B, Kim DH, Lee JH, Frankel S, Gray K, Bankoti R, Chien AJ, Levchenko A. Control of the interface between heterotypic cell populations reveals the mechanism of intercellular transfer of signaling proteins. Integr

Biol (Camb). 2015 Mar;7(3):364-72.

Pandey R, Botros MA, Nacev BA, Albig AR. Cyclosporin a disrupts notch signaling and vascular lumen maintenance. PLoS One. 2015 Mar 16;10(3):e0119279.

Crompton JG, Nacev BA, Upham T, Azoury SC, Eil R, Cameron DE, Haider AH.  Traumatic ventricular septal defect resulting in severe pulmonary hypertension. J Surg Case Rep. 2014 Oct 18;2014(10). 

Zhang F, Bhat S, Gabelli SB, Chen X, Miller MS, Nacev BA, Cheng YL, Meyers DJ, Tenney K, Shim JS, Crews P, Amzel LM, Ma D, Liu JO. Pyridinylquinazolines selectively inhibit human methionine aminopeptidase-1 in cells. J Med Chem. 2013 May 23;56(10):3996-4016.

Nacev BA, Grassi P, Dell A, Haslam SM, Liu JO. The Antifungal Drug Itraconazole Inhibits Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) Glycosylation, Trafficking, and Signaling in Endothelial Cells. J Biol Chem. 2011: 286(51):44045-56.

Nacev BA, Liu JO. Synergistic inhibition of endothelial cell proliferation, tube formation, and sprouting by cyclosporin A and itraconazole. PLoS One. 2011: 6(9):e24793.

Nacev BA, Low WK, Huang Z, Su TT, Su Z, Alkuraya H, Kasuga D, Sun W, Träger M, Braun M, Fischer G, Zhang K, Liu JO. A calcineurin-independent mechanism of angiogenesis inhibition by a nonimmunosuppressive cyclosporin A analog. J Pharmacol Exp Ther. 2011: 338(2):466-75.

Shi W, Nacev BA, Aftab BT, Head S, Rudin CM, Liu JO. Itraconazole side chain analogues: structure-activity relationship studies for inhibition of endothelial cell proliferation, vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, and hedgehog signaling. J Med Chem. 2011: 54(20):7363-74.

Wilson BA, Wang H, Nacev BA, Mease RC, Liu JO, Pomper MG, Isaacs WB. High-throughput screen identifies novel inhibitors of cancer biomarker α-methylacyl coenzyme A racemase (AMACR/P504S). Mol Cancer Ther. 2011: 10(5):825-38.

Shi W, Nacev BA, Bhat S, Liu JO.  Impact of absolute stereochemistry on the antiangiogenic and antifungal activities of itraconazole. ACS Med Chem Lett. 2010: 1(4):155-9.  

Shim JS, Matsui Y, Bhat S, Nacev BA, Xu J, Bhang HE, Dhara S, Han KC, Chong CR, Pomper MG, So A, Liu JO.  Effect of nitroxoline on angiogenesis and growth of human bladder cancer.  J Natl Cancer Inst. 2010 Dec 15;102(24):1855-73.

Xiao Q, Zhang F, Nacev BA, Liu JO, Pei D. Protein N-terminal processing: Specificity of Escherichia coli and Human Methionine Aminopeptidases. Biochemistry. 2010: 49(26):5588-5599.

Ouyang B, Knauf JA, Ain K, Nacev B, Fagin JA. Mechanisms of aneuploidy in thyroid cancer cell lines and tissues: evidence for mitotic checkpoint dysfunction without mutations in BUB1 and BUBR1. Clin Endocrinol. 2002: 56(3):341-5.

Nacev BA, Tap WD. TOMAS: revisiting PARP inhibitor combination therapy.  Lancet Oncology. 2018: 18(2):10-11.

Liu JO, Nacev BA, Xu J, Bhat S. It takes two binding sites for calcineurin and NFAT to tango. Mol Cell. 2009:33(6):676-8.

Nacev BA., Drilon AE. Apoptosis and TP53; in Pocket Oncology (ed. Vasan, Neil; Carlo, M.) 2019:31. 

Nacev BA., Segal NE. Anal Cancer; in Pocket Oncology (ed. Vasan, Neil; Carlo, M.) 2019:157-8.

Nacev BA., Tew WP. Vulvar and Vaginal Cancer; in Pocket Oncology (ed. Vasan, Neil; Carlo, M.) 2019:196-197.